

Justification Document for the Selection of a CoRAP Substance

Substance Name (Public Name):	Oxydiethylene dinitrate
Chemical Group:	Organic
EC Number:	211-745-8
CAS Number:	693-21-0
Submitted by:	Italian MSCA
Date:	22/03/2016

Note

This document has been prepared by the evaluating Member State given in the CoRAP update.

Table of Contents

1	IDENTITY OF THE SUBSTANCE	3
1.1	Other identifiers of the substance	3
2	OVERVIEW OF OTHER PROCESSES / EU LEGISLATION	4
3	HAZARD INFORMATION (INCLUDING CLASSIFICATION)	5
3.1	Classification	5
3.1.1	Harmonised Classification in Annex VI of the CLP	5
3.1.2	Self classification	6
3.1.3	Proposal for Harmonised Classification in Annex VI of the CLP	6
4	INFORMATION ON (AGGREGATED) TONNAGE AND USES	7
4.1	Tonnage and registration status	7
4.2	Overview of uses	7
5	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE	8
5.1.	Legal basis for the proposal	8
5.2.	Selection criteria met (why the substance qualifies for being in CoRAP)	8
5.3	Initial grounds for concern to be clarified under Substance Evaluation	8
5.4	Preliminary indication of information that may need to be requested to clarify the concern	10
5.5	Potential follow-up and link to risk management	10

1 IDENTITY OF THE SUBSTANCE

1.1 Other identifiers of the substance

Table: Other Substance identifiers

EC name (public):	Oxydiethylene dinitrate
IUPAC name (public):	oxydiethane-2,1-diyl dinitrate
Index number in Annex VI of the CLP Regulation:	603-033-00-4 603-033-01-1 [>25 % Phlegmatiser]
Molecular formula:	C ₄ H ₈ N ₂ O ₇
Molecular weight or molecular weight range:	196.1155
Synonyms:	DEGN

Type of substance Mono-constituent Multi-constituent UVCB

Structural formula:



2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION

Table: Completed or ongoing processes

RMOA	<input type="checkbox"/> Risk Management Option Analysis (RMOA)	
REACH Processes	Evaluation	<input type="checkbox"/> Compliance check, Final decision
		<input type="checkbox"/> Testing proposal
		<input type="checkbox"/> CoRAP and Substance Evaluation
	Authorisation	<input type="checkbox"/> Candidate List
		<input type="checkbox"/> Annex XIV
	Restriction	<input type="checkbox"/> Annex XVII ¹
Harmonised C&L	<input checked="" type="checkbox"/> Annex VI (CLP) (see section 3.1)	
Processes under other EU legislation	<input type="checkbox"/> Plant Protection Products Regulation Regulation (EC) No 1107/2009	
	<input type="checkbox"/> Biocidal Product Regulation Regulation (EU) 528/2012 and amendments	
Previous legislation	<input type="checkbox"/> Dangerous substances Directive Directive 67/548/EEC (NONS)	
	<input type="checkbox"/> Existing Substances Regulation Regulation 793/93/EEC (RAR/RRS)	
(UNEP) Stockholm convention (POPs Protocol)	<input type="checkbox"/> Assessment	
	<input type="checkbox"/> In relevant Annex	

¹ Entry no 59.

Other processes / EU legislation	<input checked="" type="checkbox"/> Other (provide further details below)
---	---

Other processes/EU legislation: Substance is included to the Annex III: LIST OF SUBSTANCES WHICH COSMETIC PRODUCTS MUST NOT CONTAIN EXCEPT SUBJECT TO THE RESTRICTIONS LAID DOWN (reference no 7) of the Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.

3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)

3.1 Classification

3.1.1 Harmonised Classification in Annex VI of the CLP

1. Oxydiethylendinitrate, diethylene glycol dinitrate, digol dinitrate

Index number: 603-033-00-4

CLP criteria:

Unst. Expl; H200: Unstable explosives.
 Acute Tox. 2; H330: Fatal if inhaled.
 Acute Tox. 1; H310: Fatal in contact with skin.
 Acute Tox. 2; H300: Fatal if swallowed.
 STOT RE 2; H373: May cause damage to organs through prolonged or repeated exposure.
 Aquatic Chronic 3; H412: Harmful to aquatic life with long lasting effects.

DSD criteria:

E; R3: Extreme risk of explosion by shock, friction, fire or other sources of ignition.
 T+; R26/27/28: Very toxic by inhalation, in contact with skin and if swallowed.
 R33: Danger of cumulative effects.
 R52-53: Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

2. Oxydiethylene dinitrate, diethylene glycol dinitrate, digol dinitrate [>25 % phlegmatiser]

Index number: 603-033-01-1

CLP criteria:

Expl. 1.1; H201: Explosive; mass explosion hazard.
 Acute Tox. 2; H330: Fatal if inhaled.
 Acute Tox. 1; H310: Fatal in contact with skin.
 Acute Tox. 2; H300: Fatal if swallowed.
 STOT RE 2; H373: May cause damage to organs through prolonged or repeated exposure.
 Aquatic Chronic 3; H412: Harmful to aquatic life with long lasting effects.

DSD criteria:

n/a

3.1.2 Self classification

- In the registration

No deviation from section 2.1.

- The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:

No deviation from section 2.1.

3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

n/a

4 INFORMATION ON (AGGREGATED) TONNAGE AND USES²

4.1 Tonnage and registration status

Table: Tonnage and registration status

From ECHA dissemination site		
<input checked="" type="checkbox"/> Full registration(s) (Art. 10)	<input type="checkbox"/> Intermediate registration(s) (Art. 17 and/or 18)	
Tonnage band (as per dissemination site)		
<input type="checkbox"/> 1 - 10 tpa	<input type="checkbox"/> 10 - 100 tpa	<input checked="" type="checkbox"/> 100 - 1000 tpa
<input type="checkbox"/> 1000 - 10,000 tpa	<input type="checkbox"/> 10,000 - 100,000 tpa	<input type="checkbox"/> 100,000 - 1,000,000 tpa
<input type="checkbox"/> 1,000,000 - 10,000,000 tpa	<input type="checkbox"/> 10,000,000 - 100,000,000 tpa	<input type="checkbox"/> > 100,000,000 tpa
<input type="checkbox"/> <1 >+ tpa (e.g. 10+ ; 100+ ; 10,000+ tpa)		<input type="checkbox"/> Confidential
<i>There is an individual and a joint submission.</i>		

4.2 Overview of uses

Table: Uses

Part 1:

<input type="checkbox"/> Manufacture	<input type="checkbox"/> Formulation	<input checked="" type="checkbox"/> Industrial use	<input type="checkbox"/> Professional use	<input type="checkbox"/> Consumer use	<input type="checkbox"/> Article service life	<input type="checkbox"/> Closed system
--------------------------------------	--------------------------------------	--	---	---------------------------------------	---	--

Industrial use:

- Use Propellants with DEGDN as plasticizer
- PROC 9: Transfer of substance or preparation into small containers (dedicated filling line, including weighing)
- ERC 5: Industrial use resulting in inclusion into or onto a matrix

² The ECHA dissemination site was accessed 19.05.2015.

5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CoRAP SUBSTANCE

5.1. Legal basis for the proposal

- Article 44(2) (refined prioritisation criteria for substance evaluation)
 Article 45(5) (Member State priority)

5.2. Selection criteria met (why the substance qualifies for being in CoRAP)

- Fulfils criteria as CMR/ Suspected CMR
 Fulfils criteria as Sensitiser/ Suspected sensitiser
 Fulfils criteria as potential endocrine disrupter
 Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB
 Fulfils criteria high (aggregated) tonnage (*tpa* > 1000)
 Fulfils exposure criteria
 Fulfils MS's (national) priorities

5.3 Initial grounds for concern to be clarified under Substance Evaluation

Hazard based concerns		
CMR <input type="checkbox"/> C <input type="checkbox"/> M <input type="checkbox"/> R	Suspected CMR ³ <input checked="" type="checkbox"/> C <input type="checkbox"/> M <input checked="" type="checkbox"/> R	<input checked="" type="checkbox"/> Potential endocrine disruptor
<input type="checkbox"/> Sensitiser	<input type="checkbox"/> Suspected Sensitiser ³	
<input type="checkbox"/> PBT/vPvB	<input checked="" type="checkbox"/> Suspected PBT/vPvB ³	<input type="checkbox"/> Other (please specify below)
Exposure/risk based concerns		
<input type="checkbox"/> Wide dispersive use	<input type="checkbox"/> Consumer use	<input type="checkbox"/> Exposure of sensitive populations
<input type="checkbox"/> Exposure of environment	<input type="checkbox"/> Exposure of workers	<input type="checkbox"/> Cumulative exposure
<input checked="" type="checkbox"/> High RCR	<input type="checkbox"/> High (aggregated) tonnage	<input type="checkbox"/> Other (please specify below)

³ CMR/Sensitiser: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory)

Suspected CMR/Suspected sensitiser: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant self-classification)

Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

The registration dossier contained chronic toxicity study using read across substance that was administered to rats by feeding. The study was conducted equivalent or similar to the OECD 452 with reliability 2 and not GLP compliant.

- The result indicated the incidence of neoplastic changes at the highest dose group in males (363 mg/kg/day) and females (434 mg/kg/day). These were hepatocellular carcinoma and cholangiofibrosis in the liver, and cell tumors in the testis (pressure on the tubules, aspermatogenesis).

The registration dossier contained reproductive toxicity study with reliability 2 and not GLP compliant. The study was conducted using read across substance in rats and equivalent or similar to OECD 416, USFDA guidelines (1966).

- The result indicated severe aspermatogenesis (408 mg / kg / day), mild-moderate increases in the amounts of interstitial tissue in testes in the F2a generation that resulted severe infertility in the F2a generation, and all litter parameters except male / female ratios were reduced in the high dose F1a litters (452 mg / kg / day).
- All litter parameters except male / female ratios were reduced in the high dose (452 mg TNG / kg / day) F1a litters.
- The food intake of the F1b dams was ~65 % that of the corresponding control dams. Their gestational product (litter size x litter weight) was ~62 % that of those control dams.

Being the effects of the reproductive toxicity study on spermatogenesis and in testes, the endocrine disruption properties should be investigated to better understanding the mode of action.

The registration dossier contained developmental toxicity study using read across substance in rats. The study was conducted equivalent or similar to the FDA guideline (1966) with reliability 2 and no GLP compliant.

- The result indicated the incidence of unossified and incompletely ossified hyoid bones at the highest dose group 59.3 mg/kg/day that was increased compared to the low 0.9 mg/kg/day and mid dose group 6.4 mg/kg/day and significantly increased compared to the control group.

The RCR for

- PROC 8b is close to 1 via inhalation exposure and above 1 via dermal exposure.
- PROC 3 is close to 1 via inhalation exposure and also the combined RCR is close to 1.

Therefore, the potential risk of the registered substance for carcinogenicity, reproductive toxicity, and exposure concern can be investigated under substance evaluation.

Suspected PBT properties:

Although estimated aquatic BCF is 3.16 L/kg (EPIWIN), the estimated (KOAWIN) Log K_{OA} is 5.78, this value has to be further clarified to assess bioaccumulation potential in air-breathing organisms. Read-across based on study for Nitroglycerin has been used in the documentation of persistency, $DT_{50(water)} > 1$ year.

Therefore, within the SEv process, PBT concern should be further clarified.

5.4 Preliminary indication of information that may need to be requested to clarify the concern

<input type="checkbox"/> Information on toxicological properties	<input type="checkbox"/> Information on physico-chemical properties
<input type="checkbox"/> Information on fate and behaviour	<input type="checkbox"/> Information on exposure
<input type="checkbox"/> Information on ecotoxicological properties	<input type="checkbox"/> Information on uses
<input type="checkbox"/> Information ED potential	<input type="checkbox"/> Other (provide further details below)

Depends on the outcome of evaluation

5.5 Potential follow-up and link to risk management

<input type="checkbox"/> Harmonised C&L	<input type="checkbox"/> Restriction	<input type="checkbox"/> Authorisation	<input type="checkbox"/> Other (provide further details)
---	--------------------------------------	--	--

Depends on the outcome of evaluation